Generic Injectables Market to Reach $152.5 Billion by 2027

Tom Smith

Project Details: – StrategyR – A Trademark of Global Industry Analysts, Inc. – Project Edition: 7. – Influencer Pool: 2719. – MarketGlass™ Platform – Our influencer driven interactive research platform draws from unique perspectives of participating executives from featured companies. New York, March 31, 2021 (GLOBE NEWSWIRE) — Reportlinker.com announces […]

Project Details: – StrategyR – A Trademark of Global Industry Analysts, Inc. – Project Edition: 7. – Influencer Pool: 2719. – MarketGlass™ Platform – Our influencer driven interactive research platform draws from unique perspectives of participating executives from featured companies.

New York, March 31, 2021 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Global Generic Injectables Industry” – https://www.reportlinker.com/p06044617/?utm_source=GNW
In addition to being a global intelligence exchange platform, MarketGlass™ is a powerful knowledge center that delivers dynamic project-focused market intelligence. Client companies will have complete insider access to the project Data stack.
– Interactive peer-to-peer and enterprise-to-enterprise ideation and market intelligence exchange is facilitated via a robust, secure, and validated process. The process draws from uniquely qualified project-specific and geographically focused executives overseeing business development, marketing and sales operations.

  • Trends & Factors – Identifying and validating local trends and factors driving each competitive marketplace. These factors include pricing variances, market trajectories, Covid-19 impact and recovery, locally active leading brands, and other parameters impacting the region in the short to medium term such as supply chain realignments.

  • Mobile Access & App – Our mobile version of the report may be accessed via our mobile app or directly for a full mobile experience.

  • Complimentary Updates – for one year. At least one update in 12-month period is normal and anytime there’s a significant change affecting the market dynamics.

  • Bespoke Updates & Team Collaborations – Clients may build a bespoke version of our report with peers on our MarketGlass™ platform which enables multidimensional data simulations.

  • Knowledge Center – clients have full-stack data access for project data they support or purchase including primary research engagement stats, companies and executives.

Abstract:
– Global Generic Injectables Market to Reach $152.5 Billion by 2027
– Amid the COVID-19 crisis, the global market for Generic Injectables estimated at US$67.7 Billion in the year 2020, is projected to reach a revised size of US$152.5 Billion by 2027, growing at aCAGR of 12.3% over the period 2020-2027. Large Molecule Injectables (Biosimilars), one of the segments analyzed in the report, is projected to record 11.9% CAGR and reach US$48.2 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Small Molecule Injectables segment is readjusted to a revised 12.5% CAGR for the next 7-year period.
– The U.S. Market is Estimated at $18.3 Billion, While China is Forecast to Grow at 16.2% CAGR
– The Generic Injectables market in the U.S. is estimated at US$18.3 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$33.3 Billion by the year 2027 trailing a CAGR of 16% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.6% and 10.8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 9.7% CAGR.

Select Competitors (Total 41 Featured) –

  • Baxter International, Inc.

  • Biocon Ltd.

  • Fresenius SE & Co. KGaA

  • Hikma Pharmaceuticals PLC

  • Lupin Ltd.

  • Mylan NV

  • Novartis AG

  • Pfizer, Inc.

  • Sanofi SA

  • Teva Pharmaceutical Industries Ltd.

Read the full report: https://www.reportlinker.com/p06044617/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Generic
Injectables by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 2: World Historic Review for Generic Injectables by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 3: World 15-Year Perspective for Generic Injectables by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets for Years 2012, 2020 & 2027

Table 4: World Current & Future Analysis for Large Molecule
Injectables (Biosimilars) by Geographic Region – USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets – Independent Analysis of Annual Sales in
US$ Million for Years 2020 through 2027 and % CAGR

Table 5: World Historic Review for Large Molecule Injectables
(Biosimilars) by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 6: World 15-Year Perspective for Large Molecule
Injectables (Biosimilars) by Geographic Region – Percentage
Breakdown of Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa for Years
2012, 2020 & 2027

Table 7: World Current & Future Analysis for Small Molecule
Injectables by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 8: World Historic Review for Small Molecule Injectables
by Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 9: World 15-Year Perspective for Small Molecule
Injectables by Geographic Region – Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa for Years
2012, 2020 & 2027

Table 10: World Current & Future Analysis for Oncology by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 11: World Historic Review for Oncology by Geographic
Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets – Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 12: World 15-Year Perspective for Oncology by Geographic
Region – Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

Table 13: World Current & Future Analysis for Infectious
Diseases by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 14: World Historic Review for Infectious Diseases by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 15: World 15-Year Perspective for Infectious Diseases by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 16: World Current & Future Analysis for Cardiology by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 17: World Historic Review for Cardiology by Geographic
Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets – Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 18: World 15-Year Perspective for Cardiology by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 19: World Current & Future Analysis for Autoimmune
Diseases by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 20: World Historic Review for Autoimmune Diseases by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 21: World 15-Year Perspective for Autoimmune Diseases by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 22: World Current & Future Analysis for Other
Applications by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 23: World Historic Review for Other Applications by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 24: World 15-Year Perspective for Other Applications by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES
Table 25: USA Current & Future Analysis for Generic Injectables
by Product Type – Large Molecule Injectables (Biosimilars) and
Small Molecule Injectables – Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 26: USA Historic Review for Generic Injectables by
Product Type – Large Molecule Injectables (Biosimilars) and
Small Molecule Injectables Markets – Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 27: USA 15-Year Perspective for Generic Injectables by
Product Type – Percentage Breakdown of Value Sales for Large
Molecule Injectables (Biosimilars) and Small Molecule
Injectables for the Years 2012, 2020 & 2027

Table 28: USA Current & Future Analysis for Generic Injectables
by Application – Oncology, Infectious Diseases, Cardiology,
Autoimmune Diseases and Other Applications – Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 29: USA Historic Review for Generic Injectables by
Application – Oncology, Infectious Diseases, Cardiology,
Autoimmune Diseases and Other Applications Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 30: USA 15-Year Perspective for Generic Injectables by
Application – Percentage Breakdown of Value Sales for Oncology,
Infectious Diseases, Cardiology, Autoimmune Diseases and Other
Applications for the Years 2012, 2020 & 2027

CANADA
Table 31: Canada Current & Future Analysis for Generic
Injectables by Product Type – Large Molecule Injectables
(Biosimilars) and Small Molecule Injectables – Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 32: Canada Historic Review for Generic Injectables by
Product Type – Large Molecule Injectables (Biosimilars) and
Small Molecule Injectables Markets – Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 33: Canada 15-Year Perspective for Generic Injectables by
Product Type – Percentage Breakdown of Value Sales for Large
Molecule Injectables (Biosimilars) and Small Molecule
Injectables for the Years 2012, 2020 & 2027

Table 34: Canada Current & Future Analysis for Generic
Injectables by Application – Oncology, Infectious Diseases,
Cardiology, Autoimmune Diseases and Other Applications –
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 35: Canada Historic Review for Generic Injectables by
Application – Oncology, Infectious Diseases, Cardiology,
Autoimmune Diseases and Other Applications Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 36: Canada 15-Year Perspective for Generic Injectables by
Application – Percentage Breakdown of Value Sales for Oncology,
Infectious Diseases, Cardiology, Autoimmune Diseases and Other
Applications for the Years 2012, 2020 & 2027

JAPAN
Table 37: Japan Current & Future Analysis for Generic
Injectables by Product Type – Large Molecule Injectables
(Biosimilars) and Small Molecule Injectables – Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 38: Japan Historic Review for Generic Injectables by
Product Type – Large Molecule Injectables (Biosimilars) and
Small Molecule Injectables Markets – Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 39: Japan 15-Year Perspective for Generic Injectables by
Product Type – Percentage Breakdown of Value Sales for Large
Molecule Injectables (Biosimilars) and Small Molecule
Injectables for the Years 2012, 2020 & 2027

Table 40: Japan Current & Future Analysis for Generic
Injectables by Application – Oncology, Infectious Diseases,
Cardiology, Autoimmune Diseases and Other Applications –
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 41: Japan Historic Review for Generic Injectables by
Application – Oncology, Infectious Diseases, Cardiology,
Autoimmune Diseases and Other Applications Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 42: Japan 15-Year Perspective for Generic Injectables by
Application – Percentage Breakdown of Value Sales for Oncology,
Infectious Diseases, Cardiology, Autoimmune Diseases and Other
Applications for the Years 2012, 2020 & 2027

CHINA
Table 43: China Current & Future Analysis for Generic
Injectables by Product Type – Large Molecule Injectables
(Biosimilars) and Small Molecule Injectables – Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 44: China Historic Review for Generic Injectables by
Product Type – Large Molecule Injectables (Biosimilars) and
Small Molecule Injectables Markets – Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 45: China 15-Year Perspective for Generic Injectables by
Product Type – Percentage Breakdown of Value Sales for Large
Molecule Injectables (Biosimilars) and Small Molecule
Injectables for the Years 2012, 2020 & 2027

Table 46: China Current & Future Analysis for Generic
Injectables by Application – Oncology, Infectious Diseases,
Cardiology, Autoimmune Diseases and Other Applications –
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 47: China Historic Review for Generic Injectables by
Application – Oncology, Infectious Diseases, Cardiology,
Autoimmune Diseases and Other Applications Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 48: China 15-Year Perspective for Generic Injectables by
Application – Percentage Breakdown of Value Sales for Oncology,
Infectious Diseases, Cardiology, Autoimmune Diseases and Other
Applications for the Years 2012, 2020 & 2027

EUROPE
Table 49: Europe Current & Future Analysis for Generic
Injectables by Geographic Region – France, Germany, Italy, UK,
Spain, Russia and Rest of Europe Markets – Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR

Table 50: Europe Historic Review for Generic Injectables by
Geographic Region – France, Germany, Italy, UK, Spain, Russia
and Rest of Europe Markets – Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 51: Europe 15-Year Perspective for Generic Injectables by
Geographic Region – Percentage Breakdown of Value Sales for
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets for Years 2012, 2020 & 2027

Table 52: Europe Current & Future Analysis for Generic
Injectables by Product Type – Large Molecule Injectables
(Biosimilars) and Small Molecule Injectables – Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 53: Europe Historic Review for Generic Injectables by
Product Type – Large Molecule Injectables (Biosimilars) and
Small Molecule Injectables Markets – Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 54: Europe 15-Year Perspective for Generic Injectables by
Product Type – Percentage Breakdown of Value Sales for Large
Molecule Injectables (Biosimilars) and Small Molecule
Injectables for the Years 2012, 2020 & 2027

Table 55: Europe Current & Future Analysis for Generic
Injectables by Application – Oncology, Infectious Diseases,
Cardiology, Autoimmune Diseases and Other Applications –
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 56: Europe Historic Review for Generic Injectables by
Application – Oncology, Infectious Diseases, Cardiology,
Autoimmune Diseases and Other Applications Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 57: Europe 15-Year Perspective for Generic Injectables by
Application – Percentage Breakdown of Value Sales for Oncology,
Infectious Diseases, Cardiology, Autoimmune Diseases and Other
Applications for the Years 2012, 2020 & 2027

FRANCE
Table 58: France Current & Future Analysis for Generic
Injectables by Product Type – Large Molecule Injectables
(Biosimilars) and Small Molecule Injectables – Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 59: France Historic Review for Generic Injectables by
Product Type – Large Molecule Injectables (Biosimilars) and
Small Molecule Injectables Markets – Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 60: France 15-Year Perspective for Generic Injectables by
Product Type – Percentage Breakdown of Value Sales for Large
Molecule Injectables (Biosimilars) and Small Molecule
Injectables for the Years 2012, 2020 & 2027

Table 61: France Current & Future Analysis for Generic
Injectables by Application – Oncology, Infectious Diseases,
Cardiology, Autoimmune Diseases and Other Applications –
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 62: France Historic Review for Generic Injectables by
Application – Oncology, Infectious Diseases, Cardiology,
Autoimmune Diseases and Other Applications Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 63: France 15-Year Perspective for Generic Injectables by
Application – Percentage Breakdown of Value Sales for Oncology,
Infectious Diseases, Cardiology, Autoimmune Diseases and Other
Applications for the Years 2012, 2020 & 2027

GERMANY
Table 64: Germany Current & Future Analysis for Generic
Injectables by Product Type – Large Molecule Injectables
(Biosimilars) and Small Molecule Injectables – Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 65: Germany Historic Review for Generic Injectables by
Product Type – Large Molecule Injectables (Biosimilars) and
Small Molecule Injectables Markets – Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 66: Germany 15-Year Perspective for Generic Injectables
by Product Type – Percentage Breakdown of Value Sales for Large
Molecule Injectables (Biosimilars) and Small Molecule
Injectables for the Years 2012, 2020 & 2027

Table 67: Germany Current & Future Analysis for Generic
Injectables by Application – Oncology, Infectious Diseases,
Cardiology, Autoimmune Diseases and Other Applications –
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 68: Germany Historic Review for Generic Injectables by
Application – Oncology, Infectious Diseases, Cardiology,
Autoimmune Diseases and Other Applications Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 69: Germany 15-Year Perspective for Generic Injectables
by Application – Percentage Breakdown of Value Sales for
Oncology, Infectious Diseases, Cardiology, Autoimmune Diseases
and Other Applications for the Years 2012, 2020 & 2027

ITALY
Table 70: Italy Current & Future Analysis for Generic
Injectables by Product Type – Large Molecule Injectables
(Biosimilars) and Small Molecule Injectables – Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 71: Italy Historic Review for Generic Injectables by
Product Type – Large Molecule Injectables (Biosimilars) and
Small Molecule Injectables Markets – Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 72: Italy 15-Year Perspective for Generic Injectables by
Product Type – Percentage Breakdown of Value Sales for Large
Molecule Injectables (Biosimilars) and Small Molecule
Injectables for the Years 2012, 2020 & 2027

Table 73: Italy Current & Future Analysis for Generic
Injectables by Application – Oncology, Infectious Diseases,
Cardiology, Autoimmune Diseases and Other Applications –
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 74: Italy Historic Review for Generic Injectables by
Application – Oncology, Infectious Diseases, Cardiology,
Autoimmune Diseases and Other Applications Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 75: Italy 15-Year Perspective for Generic Injectables by
Application – Percentage Breakdown of Value Sales for Oncology,
Infectious Diseases, Cardiology, Autoimmune Diseases and Other
Applications for the Years 2012, 2020 & 2027

UNITED KINGDOM
Table 76: UK Current & Future Analysis for Generic Injectables
by Product Type – Large Molecule Injectables (Biosimilars) and
Small Molecule Injectables – Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 77: UK Historic Review for Generic Injectables by Product
Type – Large Molecule Injectables (Biosimilars) and Small
Molecule Injectables Markets – Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 78: UK 15-Year Perspective for Generic Injectables by
Product Type – Percentage Breakdown of Value Sales for Large
Molecule Injectables (Biosimilars) and Small Molecule
Injectables for the Years 2012, 2020 & 2027

Table 79: UK Current & Future Analysis for Generic Injectables
by Application – Oncology, Infectious Diseases, Cardiology,
Autoimmune Diseases and Other Applications – Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 80: UK Historic Review for Generic Injectables by
Application – Oncology, Infectious Diseases, Cardiology,
Autoimmune Diseases and Other Applications Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 81: UK 15-Year Perspective for Generic Injectables by
Application – Percentage Breakdown of Value Sales for Oncology,
Infectious Diseases, Cardiology, Autoimmune Diseases and Other
Applications for the Years 2012, 2020 & 2027

SPAIN
Table 82: Spain Current & Future Analysis for Generic
Injectables by Product Type – Large Molecule Injectables
(Biosimilars) and Small Molecule Injectables – Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 83: Spain Historic Review for Generic Injectables by
Product Type – Large Molecule Injectables (Biosimilars) and
Small Molecule Injectables Markets – Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 84: Spain 15-Year Perspective for Generic Injectables by
Product Type – Percentage Breakdown of Value Sales for Large
Molecule Injectables (Biosimilars) and Small Molecule
Injectables for the Years 2012, 2020 & 2027

Table 85: Spain Current & Future Analysis for Generic
Injectables by Application – Oncology, Infectious Diseases,
Cardiology, Autoimmune Diseases and Other Applications –
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 86: Spain Historic Review for Generic Injectables by
Application – Oncology, Infectious Diseases, Cardiology,
Autoimmune Diseases and Other Applications Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 87: Spain 15-Year Perspective for Generic Injectables by
Application – Percentage Breakdown of Value Sales for Oncology,
Infectious Diseases, Cardiology, Autoimmune Diseases and Other
Applications for the Years 2012, 2020 & 2027

RUSSIA
Table 88: Russia Current & Future Analysis for Generic
Injectables by Product Type – Large Molecule Injectables
(Biosimilars) and Small Molecule Injectables – Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 89: Russia Historic Review for Generic Injectables by
Product Type – Large Molecule Injectables (Biosimilars) and
Small Molecule Injectables Markets – Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 90: Russia 15-Year Perspective for Generic Injectables by
Product Type – Percentage Breakdown of Value Sales for Large
Molecule Injectables (Biosimilars) and Small Molecule
Injectables for the Years 2012, 2020 & 2027

Table 91: Russia Current & Future Analysis for Generic
Injectables by Application – Oncology, Infectious Diseases,
Cardiology, Autoimmune Diseases and Other Applications –
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 92: Russia Historic Review for Generic Injectables by
Application – Oncology, Infectious Diseases, Cardiology,
Autoimmune Diseases and Other Applications Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 93: Russia 15-Year Perspective for Generic Injectables by
Application – Percentage Breakdown of Value Sales for Oncology,
Infectious Diseases, Cardiology, Autoimmune Diseases and Other
Applications for the Years 2012, 2020 & 2027

REST OF EUROPE
Table 94: Rest of Europe Current & Future Analysis for Generic
Injectables by Product Type – Large Molecule Injectables
(Biosimilars) and Small Molecule Injectables – Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 95: Rest of Europe Historic Review for Generic
Injectables by Product Type – Large Molecule Injectables
(Biosimilars) and Small Molecule Injectables Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 96: Rest of Europe 15-Year Perspective for Generic
Injectables by Product Type – Percentage Breakdown of Value
Sales for Large Molecule Injectables (Biosimilars) and Small
Molecule Injectables for the Years 2012, 2020 & 2027

Table 97: Rest of Europe Current & Future Analysis for Generic
Injectables by Application – Oncology, Infectious Diseases,
Cardiology, Autoimmune Diseases and Other Applications –
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 98: Rest of Europe Historic Review for Generic
Injectables by Application – Oncology, Infectious Diseases,
Cardiology, Autoimmune Diseases and Other Applications Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 99: Rest of Europe 15-Year Perspective for Generic
Injectables by Application – Percentage Breakdown of Value
Sales for Oncology, Infectious Diseases, Cardiology, Autoimmune
Diseases and Other Applications for the Years 2012, 2020 & 2027

ASIA-PACIFIC
Table 100: Asia-Pacific Current & Future Analysis for Generic
Injectables by Geographic Region – Australia, India, South
Korea and Rest of Asia-Pacific Markets – Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR

Table 101: Asia-Pacific Historic Review for Generic Injectables
by Geographic Region – Australia, India, South Korea and Rest
of Asia-Pacific Markets – Independent Analysis of Annual Sales
in US$ Million for Years 2012 through 2019 and % CAGR

Table 102: Asia-Pacific 15-Year Perspective for Generic
Injectables by Geographic Region – Percentage Breakdown of
Value Sales for Australia, India, South Korea and Rest of
Asia-Pacific Markets for Years 2012, 2020 & 2027

Table 103: Asia-Pacific Current & Future Analysis for Generic
Injectables by Product Type – Large Molecule Injectables
(Biosimilars) and Small Molecule Injectables – Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 104: Asia-Pacific Historic Review for Generic Injectables
by Product Type – Large Molecule Injectables (Biosimilars) and
Small Molecule Injectables Markets – Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 105: Asia-Pacific 15-Year Perspective for Generic
Injectables by Product Type – Percentage Breakdown of Value
Sales for Large Molecule Injectables (Biosimilars) and Small
Molecule Injectables for the Years 2012, 2020 & 2027

Table 106: Asia-Pacific Current & Future Analysis for Generic
Injectables by Application – Oncology, Infectious Diseases,
Cardiology, Autoimmune Diseases and Other Applications –
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 107: Asia-Pacific Historic Review for Generic Injectables
by Application – Oncology, Infectious Diseases, Cardiology,
Autoimmune Diseases and Other Applications Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 108: Asia-Pacific 15-Year Perspective for Generic
Injectables by Application – Percentage Breakdown of Value
Sales for Oncology, Infectious Diseases, Cardiology, Autoimmune
Diseases and Other Applications for the Years 2012, 2020 & 2027

AUSTRALIA
Table 109: Australia Current & Future Analysis for Generic
Injectables by Product Type – Large Molecule Injectables
(Biosimilars) and Small Molecule Injectables – Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 110: Australia Historic Review for Generic Injectables by
Product Type – Large Molecule Injectables (Biosimilars) and
Small Molecule Injectables Markets – Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 111: Australia 15-Year Perspective for Generic
Injectables by Product Type – Percentage Breakdown of Value
Sales for Large Molecule Injectables (Biosimilars) and Small
Molecule Injectables for the Years 2012, 2020 & 2027

Table 112: Australia Current & Future Analysis for Generic
Injectables by Application – Oncology, Infectious Diseases,
Cardiology, Autoimmune Diseases and Other Applications –
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 113: Australia Historic Review for Generic Injectables by
Application – Oncology, Infectious Diseases, Cardiology,
Autoimmune Diseases and Other Applications Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 114: Australia 15-Year Perspective for Generic
Injectables by Application – Percentage Breakdown of Value
Sales for Oncology, Infectious Diseases, Cardiology, Autoimmune
Diseases and Other Applications for the Years 2012, 2020 & 2027

INDIA
Table 115: India Current & Future Analysis for Generic
Injectables by Product Type – Large Molecule Injectables
(Biosimilars) and Small Molecule Injectables – Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 116: India Historic Review for Generic Injectables by
Product Type – Large Molecule Injectables (Biosimilars) and
Small Molecule Injectables Markets – Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 117: India 15-Year Perspective for Generic Injectables by
Product Type – Percentage Breakdown of Value Sales for Large
Molecule Injectables (Biosimilars) and Small Molecule
Injectables for the Years 2012, 2020 & 2027

Table 118: India Current & Future Analysis for Generic
Injectables by Application – Oncology, Infectious Diseases,
Cardiology, Autoimmune Diseases and Other Applications –
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 119: India Historic Review for Generic Injectables by
Application – Oncology, Infectious Diseases, Cardiology,
Autoimmune Diseases and Other Applications Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 120: India 15-Year Perspective for Generic Injectables by
Application – Percentage Breakdown of Value Sales for Oncology,
Infectious Diseases, Cardiology, Autoimmune Diseases and Other
Applications for the Years 2012, 2020 & 2027

SOUTH KOREA
Table 121: South Korea Current & Future Analysis for Generic
Injectables by Product Type – Large Molecule Injectables
(Biosimilars) and Small Molecule Injectables – Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 122: South Korea Historic Review for Generic Injectables
by Product Type – Large Molecule Injectables (Biosimilars) and
Small Molecule Injectables Markets – Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 123: South Korea 15-Year Perspective for Generic
Injectables by Product Type – Percentage Breakdown of Value
Sales for Large Molecule Injectables (Biosimilars) and Small
Molecule Injectables for the Years 2012, 2020 & 2027

Table 124: South Korea Current & Future Analysis for Generic
Injectables by Application – Oncology, Infectious Diseases,
Cardiology, Autoimmune Diseases and Other Applications –

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06044617/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.

__________________________

CONTACT: Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001
Next Post

Dramatic Drop in Prevalent Viruses Raises Dilemma: Masks Without end?

Masks and physical distancing are proving to have major fringe positive aspects, preserving people from receiving all kinds of health problems — not just covid-19. But it’s unclear irrespective of whether the protocols will be value the pain in the extended operate. The academics at New Hope Academy in Franklin, […]

Subscribe US Now